Molecular and clinical heterogeneity within MYC -family amplified medulloblastoma is associated with survival outcomes: A multicenter cohort study
Neuro-Oncology · 2025
DOI: 10.1093/neuonc/noae178 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Edward C Schwalbe und 14 weiteren Autor:innen. Beteiligte Einrichtung: Wolfson Childhood Cancer Research Centre, Newcastle University Centre for Cancer, Newcastle upon Tyne, UK. Hauptthemen laut MEDLINE: Medulloblastoma, Cerebellar Neoplasms, Gene Amplification, N-Myc Proto-Oncogene Protein. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, The Brain Tumour Charity, Children with Cancer UK.
Abstract (Originalsprache)
Background
MYC/MYCN are the most frequent oncogene amplifications in medulloblastoma (MB) and its primary biomarkers of high-risk (HR) disease. However, while many patients’ MYC(N)-amplified tumors are treatment-refractory, some achieve long-term survival. We therefore investigated clinicobiological heterogeneity within MYC(N)-amplified MB and determined its relevance for improved disease management.
Methods
We characterized the clinical and molecular correlates of MYC- (MYC-MB; n = 64) and MYCN-amplified MBs (MYCN-MB; n = 95), drawn from >1600 diagnostic cases.
Results
Most MYC-MBs were molecular group 3 (46/58; 79% assessable) and aged ≥3 years at diagnosis (44/64 [69%]). We identified a “canonical” very high-risk (VHR) MYC-amplified group (n = 51/62; 82%) with dismal survival irrespective of treatment (11% 5-year progression-free survival [PFS]), defined by co-occurrence with ≥1 additional established risk factor(s) (subtotal surgical-resection [STR], metastatic disease, LCA pathology), and commonly group 3/4 subgroup 2 with a high proportion of amplified cells. The majority of remaining noncanonical MYC-MBs survived (i.e. non-group 3/group 3 without other risk features; 11/62 (18%); 61% 5-year PFS). MYCN survival was primarily related to molecular group; MYCN-amplified SHH MB, and group 3/4 MB with additional risk factors, respectively defined VHR and HR groups (VHR, 39% [35/89]; 20% 5-year PFS/HR, 33% [29/89]; 46% 5-year PFS). Twenty-two out of 35 assessable MYCN-amplified SHH tumors harbored TP53 mutations; 9/12 (75%) with data were germline. MYCN-amplified group 3/4 MB with no other risk factors (28%; 25/89) had 70% 5-year PFS.
Conclusions
MYC(N)-amplified MB displays significant clinicobiological heterogeneity. Diagnostics incorporating molecular groups, subgroups, and clinical factors enable their risk assessment. VHR “canonical” MYC tumors are essentially incurable and SHH-MYCN-amplified MBs fare extremely poorly (20% survival at 5 years); both require urgent development of alternative treatment strategies. Conventional risk-adapted therapies are appropriate for more responsive groups, such as noncanonical MYC and non-SHH-MYCN MB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Wolfson Childhood Cancer Research Centre, Newcastle University Centre for Cancer, Newcastle upon Tyne, UK.
- Department of Applied Sciences, Faculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne, UK.
- Hopp Children´s Cancer Center (KiTZ), Heidelberg, Germany.
- German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany.
- Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
- University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
ORCID-Profile: Till Milde, Steven C Clifford
Förderung
- Cancer Research UK
- The Brain Tumour Charity
- Children with Cancer UK
Zitieren
APA
Schwalbe, E. C., Lindsey, J. C., Danilenko, M., Hill, R. M., Crosier, S., Ryan, S. L., Williamson, D., Castle, J., Hicks, D., Kool, M., Milde, T., Korshunov, A., Pfister, S. M., Bailey, S., & Clifford, S. C. (2025). Molecular and clinical heterogeneity within MYC -family amplified medulloblastoma is associated with survival outcomes: A multicenter cohort study. Neuro-Oncology. https://doi.org/10.1093/neuonc/noae178
Vancouver
Schwalbe EC, Lindsey JC, Danilenko M, Hill RM, Crosier S, Ryan SL, et al. Molecular and clinical heterogeneity within MYC -family amplified medulloblastoma is associated with survival outcomes: A multicenter cohort study. Neuro-Oncology. 2025. doi:10.1093/neuonc/noae178
BibTeX
@article{Schwalbe2025,
author = {Schwalbe, Edward C and Lindsey, Janet C and Danilenko, Marina and Hill, Rebecca M and Crosier, Stephen and Ryan, Sarra L and Williamson, Daniel and Castle, Jemma and Hicks, Debbie and Kool, Marcel and Milde, Till and Korshunov, Andrey and Pfister, Stefan M and Bailey, Simon and Clifford, Steven C},
title = {Molecular and clinical heterogeneity within MYC -family amplified medulloblastoma is associated with survival outcomes: A multicenter cohort study},
journal = {Neuro-Oncology},
year = {2025},
doi = {10.1093/neuonc/noae178}
}
EUVIMED